AUSTIN, Texas , March 14, 2018 (GLOBE

New Post Public Reply Private Reply Replies (0) Message Board
HoppinGator
390
AUSTIN, Texas , March 14, 2018 (GLOBE NEWSWIRE)

Bravatek Solutions, Inc. (OTCPink:BVTK) (“Bravatek” or the “Company”) announces that it will distribute through its Joint Venture (“JV”)  with AmbiCom Holdings, Inc. (“AmbiCom”),  a patented, field tested optimization software product for the expansive consumer market. 

Dr. Thomas A. Cellucci , Bravatek’s Chairman and CEO, commented: “Our Joint Venture now allows us to rapidly not only add products and capabilities into our existing markets, but now to generate new, even larger prospective consumer markets."

AmbiCom has developed a software optimization program that improves the performance of servers and workstations through the automatic evaluation and adjustment of the manufacturers’ supplied settings. This patented software application has been certified by Microsoft , IBM , VMware and Citrix in independent evaluations and represents over $12 M in previous product development investment.

We are rapidly building our JV website to sell the cloud based optimization application for consumers.  It tunes individual PCs running the Windows operating system.  The front end runs a website that users can join, try the software, and then pay for it by their credit card.  The website links to a cloud based back end that does the actual tuning of the PC.  When the front end sends the request to the backend engine, a token is passed that identifies the individual user.  The backend performs its functions, and by the use of specialized APIs, specific performance data is passed back to the front end for display to the customer.  Users can compare their performance levels of the pre and post optimized conditions.

Mr. Kevin Cornell , CEO of AmbiCom , commented: “We have already field-tested this software with consumers and expect product release within three weeks or less at a very affordable price to consumers. Based on our previous sales results for this type of software, we anticipate achieving at least $ 2 M in sales for 2018. We believe that every consumer has the right to have their PC operating at its peak performance.”

About Bravatek Solutions, Inc.
Bravatek Solutions, Inc. is a high technology security solutions portfolio provider that assists corporate entities, governments and individuals protect their organizations against both physical and cyber-attacks through its offering of the most technically-advanced, cost-effective and reliable software, tools and systems.
For more information, visit www.bravatek.com

About AmbiCom
AmbiCom specializes in a Software Optimization program currently being utilized in over 4,000,000 servers and computers worldwide.
For more information, visit www.ambicom.com

Safe Harbor Statement
This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "goal," "estimate," "anticipate" or other comparable terms. All statements other than statements of historical facts included in this news release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully market our products and services; the acceptance of our products and services by customers; our continued ability to pay operating costs and ability to meet demand for our products and services; the amount and nature of competition from other security and telecom products and services; the effects of changes in the cybersecurity and telecom markets; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, strategic alliance agreements, licensing and supplier arrangements; our ability to comply with applicable regulations; and the other risks and uncertainties described in our prior filings with the Securities and Exchange Commission . We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Media contact:
Bravatek Solutions, Inc. media@bravatek.com 1.866.490.8590


Source:

AmbiCom Holdings Inc (ABHI) Stock Research Links

ABHI Board Company Profile Buy Rating Time & Sales News Filings Financials
"Give a man a fish and he eats for a day. Teach a man to fish and he sits in a boat drinking all day."
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 230

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 225

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 308

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 412

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 106

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 130

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 288

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 131

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 127

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 134

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading

Top 5 Most Recently Viewed Articles

Kinetic Seas Incorporated Secures First Customer Success

Updated Category News Views 56

Kinetic Seas Incorporated Secures First Customer and Financial Growth Kinetic Seas Incorporated (OTC: ECGR) is excited to announce the signing of its first customer, along with impressive revenue results for the second quarter. This milestone marks a significant step forward as the company pursues its goals in the artificial intelligence sector. Second Quarter Revenue...

Continue Reading
Webinar Guide for Veterans to Maximize Benefits Offered by CCK Law

Updated Category News Views 134

Helping Veterans Discover VA Benefits with a Free Webinar Chisholm Chisholm & Kilpatrick LTD (CCK Law), a preeminent veterans disability law firm, is excited to introduce a free, on-demand webinar aimed at assisting veterans in uncovering valuable VA benefits that many may be unaware of. Insights from the Experts The webinar, dubbed "Biggest Benefits Veterans Overlook,"...

Continue Reading
Tech Market Shifts: Navigating Opportunities and Challenges Ahead

Updated Category News Views 161

Understanding Recent Market Dynamics In recent weeks, global markets have been experiencing heightened volatility, particularly in the technology sector. With various significant events unfolding—including new political leadership in Japan and shifts in economic data—investors are carefully analyzing these developments to navigate potential risks and opportunities....

Continue Reading
Michael Beland Joins Advance Auto Parts as Chief Accounting Officer

Updated Category News Views 720

Welcome Michael Beland to Advance Auto Parts Advance Auto Parts, Inc. (NYSE: AAP), known for its significant role in the automotive aftermarket, recently made an important announcement regarding its executive leadership. The company has appointed Michael Beland as the new senior vice president, controller, and chief accounting officer, marking a pivotal addition to their...

Continue Reading
Recall Movement Against Governor Newsom Gains Momentum

Updated Category News Views 276

Recall Movement Gains Traction in California In an unprecedented move, SavingCalifornia.vote has taken a significant step to initiate a recall against Governor Gavin Newsom. This initiative marks a pivotal moment in California's political landscape. The organization is gathering support and will soon submit the official notice of intent to recall, alongside the necessary...

Continue Reading